Inovio Pharmaceuticals (INO) furnishes Q2 2025 financial results press release

Rhea-AI Filing Summary

Inovio Pharmaceuticals, Inc. filed a current report to share that it issued a press release with its financial results for the quarter ended June 30, 2025. The press release, dated August 12, 2025, is attached as Exhibit 99.1 and incorporated by reference.

The company is using this report under Item 2.02, which covers results of operations and financial condition. The information in Item 2.02 and Exhibit 99.1 is being furnished, rather than filed, meaning it is not subject to certain liability provisions of the Exchange Act or automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001055726FALSE00010557262025-08-122025-08-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

Inovio Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-14888

33-0969592

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

660 W. Germantown Pike Suite 110

Plymouth Meeting, PA 19462

(Address of principal executive offices, including zip code)

(267) 440-4200

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

INO

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 2.02    Results of Operations and Financial Condition.

On August 12, 2025, Inovio Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number
99.1			Press Release, dated August 12, 2025 (filed herewith)
104			Cover Page Interactive Data File (formatted as inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INOVIO PHARMACEUTICALS, INC.

Date: August 12, 2025

By:

/s/ Peter Kies

Peter Kies

Chief Financial Officer

FAQ

What did Inovio Pharmaceuticals (INO) disclose in this 8-K filing?

Inovio Pharmaceuticals disclosed that it issued a press release with financial results for the quarter ended June 30, 2025. The release, dated August 12, 2025, is attached as Exhibit 99.1 and incorporated by reference into this current report.

Which period’s results are covered in Inovio Pharmaceuticals’ August 12, 2025 update?

The update covers financial results for the quarter ended June 30, 2025. Inovio Pharmaceuticals furnished a press release as Exhibit 99.1, dated August 12, 2025, summarizing its operating and financial performance for that specific quarterly period.

Is the Inovio Pharmaceuticals (INO) earnings press release considered filed with the SEC?

No, the earnings press release is furnished, not filed. The company states that Item 2.02 and Exhibit 99.1 are furnished under General Instruction B.2 and are not deemed filed or subject to Section 18 liabilities, unless specifically incorporated by reference.

Where can investors find the detailed Q2 2025 results for Inovio Pharmaceuticals?

Investors can find detailed Q2 2025 results in Exhibit 99.1, which is the press release dated August 12, 2025. This exhibit is attached to the current report on Form 8-K and incorporated by reference for more complete financial information.

What exhibits are included in Inovio Pharmaceuticals’ August 12, 2025 Form 8-K?

The filing includes two exhibits: 99.1 and 104. Exhibit 99.1 is the press release dated August 12, 2025, with quarterly financial results. Exhibit 104 is the cover page interactive data file formatted as inline XBRL for electronic reporting.

Who signed the Inovio Pharmaceuticals (INO) Form 8-K for the June 30, 2025 quarter?

The Form 8-K was signed by Peter Kies, Chief Financial Officer. The signature block shows that Inovio Pharmaceuticals, Inc. caused the report to be signed on its behalf on August 12, 2025, by CFO Peter Kies as the duly authorized officer.